These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36717798)

  • 1. Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis.
    Chen X; Wen Q; Kou L; Xie X; Li J; Li Y
    BMC Cancer; 2023 Jan; 23(1):107. PubMed ID: 36717798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of PARP inhibitors in the treatment of prostatic cancer: a systematic review and network meta-analysis.
    Huang Y; He H; Liang L; Zhang Y; Peng K; Wang Y; Wu J; Long X; Kairemo K; Goldberg H; Mendez LC; Gu D
    Chin Clin Oncol; 2024 Aug; 13(4):64. PubMed ID: 39238347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis.
    Luo J; Ou S; Wei H; Qin X; Jiang Q
    Front Oncol; 2022; 12():815265. PubMed ID: 35756600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of PARP Inhibitor Therapy in Advanced Ovarian Cancer: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
    Chen J; Wu X; Wang H; Lian X; Li B; Zhan X
    Curr Comput Aided Drug Des; 2024; 20(6):736-751. PubMed ID: 37691198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
    Gong H; Nie D; Huang Y; Li Z
    Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
    Rimel BJ; Enserro D; Bender DP; Jackson CG; Tan A; Alluri N; Borowsky M; Moroney J; Hendrickson AW; Backes F; Swisher E; Powell M; MacKay H
    Cancer; 2024 Apr; 130(8):1234-1245. PubMed ID: 38127487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
    Zhou JX; Feng LJ; Zhang X
    Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials.
    Liu Y; Meng J; Wang G
    Drug Des Devel Ther; 2018; 12():3013-3019. PubMed ID: 30271116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials.
    Bao S; Yue Y; Hua Y; Zeng T; Yang Y; Yang F; Yan X; Sun C; Yang M; Fu Z; Huang X; Li J; Wu H; Li W; Zhao Y; Yin Y
    Ann Transl Med; 2021 Aug; 9(15):1229. PubMed ID: 34532366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
    Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
    Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
    Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis.
    Cai Z; Liu C; Chang C; Shen C; Yin Y; Yin X; Jiang Z; Zhao Z; Mu M; Cao D; Zhang L; Zhang B
    Pharmacol Res; 2021 Oct; 172():105808. PubMed ID: 34389457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
    Arend RC; O'Malley DM; Banerjee S; McLaurin K; Davidson R; Long GH
    Adv Ther; 2022 Jan; 39(1):328-345. PubMed ID: 34727316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
    Lee JM; Cimino-Mathews A; Peer CJ; Zimmer A; Lipkowitz S; Annunziata CM; Cao L; Harrell MI; Swisher EM; Houston N; Botesteanu DA; Taube JM; Thompson E; Ogurtsova A; Xu H; Nguyen J; Ho TW; Figg WD; Kohn EC
    J Clin Oncol; 2017 Jul; 35(19):2193-2202. PubMed ID: 28471727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
    Chen Y; Du H
    Biomed Pharmacother; 2018 Mar; 99():552-560. PubMed ID: 29895102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials.
    Sun W; Li J; Zhang Z; Su X
    J Clin Pharm Ther; 2021 Apr; 46(2):241-255. PubMed ID: 33135237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
    Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
    Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
    Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials.
    Li J; Zhang Z
    J Chemother; 2021 Nov; 33(7):452-461. PubMed ID: 33583364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.